144 related articles for article (PubMed ID: 12402932)
1. Cardiovascular risk reduction with pioglitazone.
Cardiovasc J S Afr; 2002; 13(4):218. PubMed ID: 12402932
[No Abstract] [Full Text] [Related]
2. Cardiovascular effects of troglitazone.
Umland EM; Romanelli AM
Ann Pharmacother; 1999 Feb; 33(2):229-32. PubMed ID: 10084419
[No Abstract] [Full Text] [Related]
3. Pioglitazone: the future.
Brunetti P
Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
[No Abstract] [Full Text] [Related]
4. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
5. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
6. [Prospective pioglitazone clinical trial in macrovascular events].
Asanuma H; Kitakaze M
Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
[No Abstract] [Full Text] [Related]
7. Pioglitazone.
Lawrence JM; Reckless JP
Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
9. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
10. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
11. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Donnelly R
Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
[TBL] [Abstract][Full Text] [Related]
13. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
Goldstein BJ
Clin Ther; 2002 Aug; 24(8):1358-60; author reply 1360-2. PubMed ID: 12240785
[No Abstract] [Full Text] [Related]
14. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
15. [New prospects for the type 2 diabetic patient. Delaying disease progression].
MMW Fortschr Med; 2000 Nov; 142(46):56-7. PubMed ID: 11138590
[No Abstract] [Full Text] [Related]
16. Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
Buse JB
Am J Manag Care; 2000 Aug; 6(13 Suppl):S710-7. PubMed ID: 11183423
[No Abstract] [Full Text] [Related]
17. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
18. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
19. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
20. Warner Lambert/Sankyo diabetes drug nears market.
Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
